everolimus
Not Tagged
['kcsm,(-skcsm)', 'everest', 'improve', 'rcc,(-irccs),(-srcc),(-urcc)']
dr. chria ryan reports on everest ph3 trial. 1 year of adjuvant everolimus for intermediate to high risk rcc #kcsm everolimus improved rfs in in the very high risk but missed the statistical significance threshold for the overall population. no improvement in os #asco22
Medical oncologist - Developmental Therapeutics - NIH/NCI - opinions my own - retweet is not endorsement